Literature DB >> 21436140

Drug discovery and development focusing on existing medicines: drug re-profiling strategy.

Tohru Mizushima1.   

Abstract

As a new strategy for drug discovery and development, I focus on drug re-profiling as a way to identify new treatments for diseases. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have already been confirmed clinically and approved for use, are examined comprehensively at the molecular level and the results used for the development of new medicines. This strategy is based on the fact that we still do not understand the underlying mechanisms of action of many existing medicines, and as such the cellular responses that give rise to their main effects and side effects are yet to be elucidated. To this extent, identification of the mechanisms underlying the side effects of medicines offers a means for us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines for the treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436140     DOI: 10.1093/jb/mvr032

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  14 in total

1.  Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-02-15       Impact factor: 2.649

2.  Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease.

Authors:  Ken-Ichiro Tanaka; Shota Kurotsu; Teita Asano; Naoki Yamakawa; Daisuke Kobayashi; Yasunobu Yamashita; Hiroshi Yamazaki; Tomoaki Ishihara; Hiroshi Watanabe; Toru Maruyama; Hidekazu Suzuki; Tohru Mizushima
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

3.  Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells.

Authors:  Kaori Yama; Keisuke Sato; Natsuki Abe; Yu Murao; Ryosuke Tatsunami; Yoshiko Tampo
Journal:  Redox Biol       Date:  2014-12-10       Impact factor: 11.799

4.  Identification of approved drugs that inhibit the binding of amyloid β oligomers to ephrin type-B receptor 2.

Authors:  Koichiro Suzuki; Takahiro Aimi; Tomoaki Ishihara; Tohru Mizushima
Journal:  FEBS Open Bio       Date:  2016-04-01       Impact factor: 2.693

5.  Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.

Authors:  Teita Asano; Shuji Aida; Shintaro Suemasu; Kayoko Tahara; Ken-ichiro Tanaka; Tohru Mizushima
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

6.  Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome.

Authors:  Teita Asano; Ken-Ichiro Tanaka; Arisa Tada; Hikaru Shimamura; Rikako Tanaka; Hiroki Maruoka; Mitsuko Takenaga; Tohru Mizushima
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

7.  Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice.

Authors:  Ken-Ichiro Tanaka; Tomomi Niino; Tomoaki Ishihara; Ayaka Takafuji; Takahiro Takayama; Yuki Kanda; Toshifumi Sugizaki; Fumiya Tamura; Shota Kurotsu; Masahiro Kawahara; Tohru Mizushima
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

8.  Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation.

Authors:  Keisuke Sato; Kaori Yama; Yu Murao; Ryosuke Tatsunami; Yoshiko Tampo
Journal:  Redox Biol       Date:  2013-11-19       Impact factor: 11.799

9.  Discovery of novel GPVI receptor antagonists by structure-based repurposing.

Authors:  Lewis Taylor; Sridhar R Vasudevan; Chris I Jones; Jonathan M Gibbins; Grant C Churchill; R Duncan Campbell; Carmen H Coxon
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

10.  Metformin attenuates lung fibrosis development via NOX4 suppression.

Authors:  Nahoko Sato; Naoki Takasaka; Masahiro Yoshida; Kazuya Tsubouchi; Shunsuke Minagawa; Jun Araya; Nayuta Saito; Yu Fujita; Yusuke Kurita; Kenji Kobayashi; Saburo Ito; Hiromichi Hara; Tsukasa Kadota; Haruhiko Yanagisawa; Mitsuo Hashimoto; Hirofumi Utsumi; Hiroshi Wakui; Jun Kojima; Takanori Numata; Yumi Kaneko; Makoto Odaka; Toshiaki Morikawa; Katsutoshi Nakayama; Hirotsugu Kohrogi; Kazuyoshi Kuwano
Journal:  Respir Res       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.